BriaCell Therapeutics Corp. Announces Results of Shareholder Meeting
Annual Meeting Results: BriaCell Therapeutics Corp. held its annual general meeting on February 5, 2025, where shareholders voted overwhelmingly in favor of all proposed resolutions, including the re-appointment of auditors and the election of new directors.
Voting Outcomes: A total of 36.26% of common shares were voted, with individual director candidates receiving between 86.57% to 88.44% approval from shareholders.
Discover Tomorrow's Bullish Stocks Today
Analyst Views on BCTXW
No data
About the author
BRIACELL THERAPEUTICS COMPLETES $30 MILLION PUBLIC OFFERING
Company Announcement: BRIACELL THERAPEUTICS has announced the closing of a public offering.
Financial Details: The offering raised a total of US$30 million.
BriaCell Chosen to Showcase Phase 2 and 3 Clinical Findings at SABCS® 2025
BriaCell's Presentations at SABCS: BriaCell Therapeutics will present three clinical and one preclinical posters at the 2025 San Antonio Breast Cancer Symposium, showcasing key biomarker data and survival results from their studies on Bria-IMT™ and other therapies for metastatic breast cancer.
Significant Data Sharing: The presentations include late-breaking clinical posters that aim to provide substantial data to leading breast cancer experts, with the goal of improving clinical outcomes for cancer patients.
Poster Presentation Details: Key presentations include topics on the impact of prior therapy and biomarkers in the Bria-ABC Phase 3 Trial, survival results from the Phase II Bria-IMT vaccine, and cytokine signatures as biomarkers of clinical benefit in breast cancer vaccination.
Company Overview: BriaCell is a clinical-stage biotechnology company focused on developing innovative immunotherapies to enhance cancer care, with more information available on their website.
